<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6928875</article-id><article-id pub-id-type="doi">10.3390/ijms20235952</article-id><article-id pub-id-type="publisher-id">ijms-20-05952</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Bingpeng</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref><xref ref-type="author-notes" rid="fn1-ijms-20-05952">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Zijiao</given-names></name><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref><xref ref-type="author-notes" rid="fn1-ijms-20-05952">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2855-9837</contrib-id><name><surname>Chu</surname><given-names>Hin</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref><xref ref-type="author-notes" rid="fn1-ijms-20-05952">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Gabriella</given-names></name><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Tsang</surname><given-names>Jessica Oi-Ling</given-names></name><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Pok-Man</given-names></name><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Shuofeng</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Yip</surname><given-names>Cyril Chik-Yan</given-names></name><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Feifei</given-names></name><xref ref-type="aff" rid="af3-ijms-20-05952">3</xref><xref ref-type="aff" rid="af4-ijms-20-05952">4</xref><xref ref-type="aff" rid="af5-ijms-20-05952">5</xref></contrib><contrib contrib-type="author"><name><surname>Kao</surname><given-names>Richard Yi-Tsun</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Sze</surname><given-names>Kong-Hung</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref></contrib><contrib contrib-type="author"><name><surname>Lau</surname><given-names>Susanna Kar-Pui</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref><xref ref-type="aff" rid="af6-ijms-20-05952">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6336-6657</contrib-id><name><surname>Chan</surname><given-names>Jasper Fuk-Woo</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref><xref ref-type="aff" rid="af3-ijms-20-05952">3</xref><xref ref-type="aff" rid="af6-ijms-20-05952">6</xref><xref rid="c1-ijms-20-05952" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Yuen</surname><given-names>Kwok-Yung</given-names></name><xref ref-type="aff" rid="af1-ijms-20-05952">1</xref><xref ref-type="aff" rid="af2-ijms-20-05952">2</xref><xref ref-type="aff" rid="af3-ijms-20-05952">3</xref><xref ref-type="aff" rid="af6-ijms-20-05952">6</xref><xref ref-type="aff" rid="af7-ijms-20-05952">7</xref><xref rid="c1-ijms-20-05952" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-20-05952"><label>1</label>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region; <email>ybp1205@hku.hk</email> (B.Y.); <email>hinchu@hku.hk</email> (H.C.); <email>yuansf@hku.hk</email> (S.Y.); <email>rytkao@hku.hk</email> (R.Y.-T.K.); <email>khsze@hku.hk</email> (K.-H.S.); <email>skplau@hku.hk</email> (S.K.-P.L.)</aff><aff id="af2-ijms-20-05952"><label>2</label>Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region; <email>u3006001@hku.hk</email> (Z.Z.); <email>gchan2@hku.hk</email> (G.C.); <email>joltsang@connect.hku.hk</email> (J.O.-L.T.); <email>vangor@hku.hk</email> (P.-M.L.); <email>yipcyril@hku.hk</email> (C.C.-Y.Y.)</aff><aff id="af3-ijms-20-05952"><label>3</label>Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou 571101, China &#x00026; The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region; <email>yinfeifeiff@163.com</email></aff><aff id="af4-ijms-20-05952"><label>4</label>Department of Pathogen Biology, Hainan Medical University, Haikou, Hainan 571101, China</aff><aff id="af5-ijms-20-05952"><label>5</label>Key Laboratory of Translational Tropical Medicine, Hainan Medical University, Haikou 571101, China</aff><aff id="af6-ijms-20-05952"><label>6</label>Carol Yu Centre for Infection, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</aff><aff id="af7-ijms-20-05952"><label>7</label>The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</aff><author-notes><corresp id="c1-ijms-20-05952"><label>*</label>Correspondence: <email>jfwchan@hku.hk</email> (J.F.-W.C.); <email>kyyuen@hku.hk</email> (K.-Y.Y.); Tel.: +852-2255-2413 (J.F.-W.C. &#x00026; K.-Y.Y.); Fax: +852-2255-1241 (J.F.-W.C. &#x00026; K.-Y.Y.)</corresp><fn id="fn1-ijms-20-05952"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>20</volume><issue>23</issue><elocation-id>5952</elocation-id><history><date date-type="received"><day>21</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16) are the most common causes of hand, foot, and mouth disease. Severe EV-A71 and CV-A16 infections may be associated with life-threatening complications. However, the pathogenic mechanisms underlying these severe clinical and pathological features remain incompletely understood. Lipids are known to play critical roles in multiple stages of the virus replication cycle. The specific lipid profile induced upon virus infection is required for optimal virus replication. The perturbations in the host cell lipidomic profiles upon enterovirus infection have not been fully characterized. To this end, we performed ultra-high performance liquid chromatography&#x02013;electrospray ionization&#x02013;quadrupole&#x02013;time of flight-mass spectrometry (UPLC-ESI-Q-TOF-MS)-based lipidomics to characterize the change in host lipidome upon EV-A71 and CV-A16 infections. Our results revealed that 47 lipids within 11 lipid classes were significantly perturbed after EV-A71 and CV-A16 infection. Four polyunsaturated fatty acids (PUFAs), namely, arachidonic acid (AA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA), were consistently upregulated upon EV-A71 and CV-A16 infection. Importantly, exogenously supplying three of these four PUFAs, including AA, DHA, and EPA, in cell cultures significantly reduced EV-A71 and CV-A16 replication. Taken together, our results suggested that enteroviruses might specifically modulate the host lipid pathways for optimal virus replication. Excessive exogenous addition of lipids that disrupted this delicate homeostatic state could prevent efficient viral replication. Precise manipulation of the host lipid profile might be a potential host-targeting antiviral strategy for enterovirus infection.</p></abstract><kwd-group><kwd>enterovirus</kwd><kwd>fatty acid</kwd><kwd>lipidomics</kwd><kwd>UPLC-ESI-Q-TOF-MS</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-20-05952"><title>1. Introduction</title><p>Enteroviruses are non-enveloped viruses belonging to the genus <italic>Enterovirus</italic> in the family <italic>Picornaviridae</italic> that are associated with important human and mammalian diseases. Enteroviruses have non-segmented, single-stranded, positive-sense RNA genomes that measure around 7.5 kilobases [<xref rid="B1-ijms-20-05952" ref-type="bibr">1</xref>]. There are 15 species in the genus <italic>Enterovirus</italic>, namely, <italic>Enterovirus</italic> A to L and <italic>Rhinovirus</italic> A to C. Among members of the species <italic>Enterovirus</italic> A, enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16) are two of the most common causes of recurrent community outbreaks of hand, foot, and mouth disease (HFMD) among children worldwide and particularly in the Asia&#x02013;Pacific region. For example, in mainland China, recurrent large outbreaks of HFMD involving &#x0003e;120,000&#x02013;600,000 patients have been reported since 1998 [<xref rid="B2-ijms-20-05952" ref-type="bibr">2</xref>,<xref rid="B3-ijms-20-05952" ref-type="bibr">3</xref>]. Outbreaks of EV-A71 and CV-A16 infections with severe or fatal cases have also been reported in Malaysia, Hong Kong, Japan, Singapore, Taiwan, Thailand, Vietnam, and Australia [<xref rid="B4-ijms-20-05952" ref-type="bibr">4</xref>]. Importantly, severe EV-A71 and CV-A16 infections are associated with life-threatening complications, such as aseptic meningitis, encephalitis, myocarditis, non-cardiogenic pulmonary edema with respiratory failure, and death [<xref rid="B1-ijms-20-05952" ref-type="bibr">1</xref>,<xref rid="B5-ijms-20-05952" ref-type="bibr">5</xref>]. However, the pathogenic mechanisms underlying these clinical and pathological features are incompletely understood. </p><p>Lipids are known to play crucial roles in multiple stages of the viral replication cycle. Viruses, including enteroviruses, may utilize lipids as receptors or entry co-factors for virus entry [<xref rid="B6-ijms-20-05952" ref-type="bibr">6</xref>,<xref rid="B7-ijms-20-05952" ref-type="bibr">7</xref>], as building blocks or regulators of the viral replication complex [<xref rid="B8-ijms-20-05952" ref-type="bibr">8</xref>,<xref rid="B9-ijms-20-05952" ref-type="bibr">9</xref>], as well as signaling factors to facilitate the cellular distribution of viral proteins, and the trafficking, assembly, and release of virus particles [<xref rid="B10-ijms-20-05952" ref-type="bibr">10</xref>,<xref rid="B11-ijms-20-05952" ref-type="bibr">11</xref>]. Interestingly, viruses require a repertoire of host lipids to complete their life cycle. Inhibitions of key lipogenesis enzymes can downregulate virus replication [<xref rid="B12-ijms-20-05952" ref-type="bibr">12</xref>]. However, when supplied in excess, these lipids can similarly perturb efficient virus replication [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>]. Together, these evidences suggest that the complete lipid landscape induced upon virus infection is required for optimal virus replication. The perturbations in the host cell lipidomic profiles upon enterovirus infection have not been fully characterized.</p><p>In this study, we first established a robust platform for lipidomic analysis of enterovirus infections. We then applied this platform to perform an unbiased analysis of the host lipidome changes induced by EV-A71 and CV-A16 in rhabdomyosarcoma (RD) cells. We found that these enteroviruses perturbed the expression of multiple lipid classes in the host cells during infection. Importantly, exogenously supplying selected fatty acids significantly inhibited viral replication. These findings provided novel insights into the role of lipids in the pathogenesis and antiviral treatment of enterovirus infection.</p></sec><sec sec-type="results" id="sec2-ijms-20-05952"><title>2. Results</title><sec id="sec2dot1-ijms-20-05952"><title>2.1. Analytical Method Validation</title><p>To establish a reliable platform for lipidomic analysis, we first validated the lipid coverage and liquid chromatography-mass spectrometry (LC-MS) system stability. We applied 15 representative lipid internal standards that covered 14 lipid classes in the current study (<xref ref-type="app" rid="app1-ijms-20-05952">Table S1</xref>) [<xref rid="B14-ijms-20-05952" ref-type="bibr">14</xref>]. The retention time shift and mass accuracy of lipid standards ranged from &#x02212;0.12%&#x02013;4.73% and &#x02212;7.7&#x02013;4.13 ppm, respectively. The coefficient of variation (CV) of all internal standards in cell samples and the QC samples were lower than 18% and 15%, respectively. These results indicated that the operation repeatability was satisfactory. To evaluate the stability of the analytical batch, the CV values of all mass features in the quality control (QC) samples were calculated. A total of 98.70% and 93.32% of the features measured in the negative and positive mode, respectively, exhibited CV values of &#x0003c;30%, indicating that the analytical batch was stable with minimal variations. Taken together, these results showed that the analytical method was reliable and the observed differences among the test samples represented true physiological differences, rather than technical errors [<xref rid="B15-ijms-20-05952" ref-type="bibr">15</xref>].</p></sec><sec id="sec2dot2-ijms-20-05952"><title>2.2. Lipidomic Profile Analysis</title><p>To investigate the host cell lipid metabolism perturbations upon enterovirus infection, we compared the lipidomic profile of RD cells infected with EV-A71 or CV-A16 with that of the mock-infected cells. The lipid features in the mass spectrometry (MS) features list were first normalized with the DNA concentration of each sample. Then, the normalized list was imported into the MetaboAnalyst and SIMCA-P software for further analysis. The partial least squares discriminant analysis (PLS-DA) score plots in both the negative and positive modes were applied to visualize the distribution of lipids and discrimination between virus-infected and mock-infected samples. As shown in <xref ref-type="fig" rid="ijms-20-05952-f001">Figure 1</xref>, the lipid profiles of the three types of samples were clearly separated in both the negative and positive modes. This indicated that many lipid MS features exhibited obvious changes and some MS features contributed to the discrimination pattern among the three groups under the PLS-DA pattern recognition. In addition, the principal component analysis (PCA) score plots were applied to visualize the distribution of the lipids and the relatedness of virus-infected and mock-infected samples. As shown in <xref ref-type="app" rid="app1-ijms-20-05952">Figure S1</xref>, all cell samples were distributed in the statistical confidence region based on the Hotelling&#x02019;s T2 test. The PCA results showed that the cell samples in the current study were not outliers.</p><p>To further characterize the lipidomic changes upon EV-A71 and CV-A16 infection, a heat map was constructed based on the lipid MS features list. As shown in <xref ref-type="fig" rid="ijms-20-05952-f002">Figure 2</xref>, different patterns of lipidomic changes were observed in the negative mode (<xref ref-type="fig" rid="ijms-20-05952-f002">Figure 2</xref>A) and positive mode (<xref ref-type="fig" rid="ijms-20-05952-f002">Figure 2</xref>B). While the lipid profiles of the three types of samples were less different in the negative mode (<xref ref-type="fig" rid="ijms-20-05952-f002">Figure 2</xref>A), the lipid profiles of the EV-A71 and CV-A16-infected samples were markedly different from that of the mock-infected samples in the positive mode (<xref ref-type="fig" rid="ijms-20-05952-f002">Figure 2</xref>B). The common pattern of the two detection modes was that most lipid MS features in EV-A71-infected cells were in higher abundance than those of the mock-infected controls.</p></sec><sec id="sec2dot3-ijms-20-05952"><title>2.3. Significantly Perturbed Lipid Features in Enterovirus Infection</title><p>To select the significantly perturbed lipid features in the lipid profiles of EV-A71 or CV-A16-infected RD cells, univariate and multivariate data analyses based on the lipid MS features list were performed. In the univariate analysis, a total of 622 features (215 known + 407 unknown lipid features) were detected in the negative mode and 1496 features (413 known + 1083 unknown lipid features) were detected in the positive mode. After applying the selection criteria of an adjusted <italic>p</italic> &#x0003c; 0.05, a total of 31 significantly different features (4.98%, negative mode) and 451 features (30.15%, positive mode) were identified between the EV-A71-infected vs. mock-infected samples. A total of 58 significantly different features (9.32%, negative mode) and 273 features (18.25%, positive mode) were identified between CV-A16-infected vs. mock-infected samples. In the multivariate analysis, these cross-validated parameters were satisfactory for the OPLS-DA model (<xref ref-type="app" rid="app1-ijms-20-05952">Table S2</xref>). Our model also satisfied the permutation test (100 times), which was based on the PLS-DA model when the results of the EV-A71 or CV-A16-infected samples were compared with that of the mock-infected samples (<xref ref-type="app" rid="app1-ijms-20-05952">Figure S2</xref>). Overall, these results demonstrated that our validated statistical model reliably identified the significantly perturbed lipid features in our comparative lipidomic analysis between the virus-infected and mock-infected samples.</p></sec><sec id="sec2dot4-ijms-20-05952"><title>2.4. Lipid Changes Specific to EV-A71 and CV-A16 Infection</title><p>In order to identify specific lipid changes in EV-A71 and CV-A16 infections, the significant lipid features were grouped and annotated using the MS-DIAL software [<xref rid="B16-ijms-20-05952" ref-type="bibr">16</xref>]. Potential precursor ions were used to perform further MS/MS experiments to obtain their fragmentation patterns and the MS/MS spectra of some representative lipids were shown in <xref ref-type="app" rid="app1-ijms-20-05952">Figure S3</xref>. A total of 47 significantly changed lipids were identified when the three groups of samples were compared in pairs. These lipids included those belonging to the phospholipid, glycerolipid, fatty acyls, and sphingolipid categories [<xref rid="B17-ijms-20-05952" ref-type="bibr">17</xref>]. Detailed information of these 47 identified lipids was listed in <xref rid="ijms-20-05952-t001" ref-type="table">Table 1</xref> [<xref rid="B18-ijms-20-05952" ref-type="bibr">18</xref>]. These 47 lipids belonged to 11 lipid classes, including cardiolipin (CL), diacylglycerol (DAG), ether-linked lysophosphatidylcholine (EtherLPC), ether-linked lysophosphatidylethanolamine (EtherLPE), ether-linked phosphatidylethanolamine (EtherPE), free fatty acids (FFA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), sphingomyelin (SM), and triacylglycerol (TAG) (<xref ref-type="fig" rid="ijms-20-05952-f003">Figure 3</xref>A) [<xref rid="B14-ijms-20-05952" ref-type="bibr">14</xref>]. Among them, TAG (16/47, 34.0%), EtherPE (8/47, 17.0%), and FFA (5/47, 10.6%) were the three most perturbed lipid classes upon EV-A71 and CV-A16 infection. </p><p>In the group-to-group comparison, 3/47 (6.4%) lipids belonging to diacylglycerols (DAG) and triacylglycerols (TAG) were uniquely different between EV-A71-infected vs. mock-infected cells, 15/47 (31.9%) lipids belonging to SM, FFA, TAG, LPE, and EtherPE were uniquely different between CV-A16-infected vs. mock-infected cells, and 3/47 (6.4%) lipids belonging to EtherPE and PC were uniquely different between EV-A71-infected vs. CV-A16-infected cells (<xref ref-type="fig" rid="ijms-20-05952-f003">Figure 3</xref>B). In addition, 15/47 (31.9%) lipids belonging to TAG, FFA, and LPC were significantly different in both EV-A71-infected and CV-A16-infected vs. mock-infected cells (<xref ref-type="fig" rid="ijms-20-05952-f003">Figure 3</xref>B). Taken together, these results showed that the biogenesis of diverse intracellular lipids was significantly perturbed upon EV-A71 and CV-A16 infections.</p></sec><sec id="sec2dot5-ijms-20-05952"><title>2.5. Characterization of the Specific Lipid Changes in EV-A71 and CV-A16 Infection</title><p>To further characterize the significant lipids perturbed in EV-A71 and CV-A16 infection, we next compared the direction, magnitude, and statistical significance of the EV-A71- and CV-A16-induced lipid changes in RD cells with those of the mock-infected cells at four-hours post infection (hpi) (<xref ref-type="fig" rid="ijms-20-05952-f004">Figure 4</xref>). EV-A71-infected cells exhibited a total of 18 significantly perturbed lipids belonging to four lipid classes, including FFA, DAG, LPC, and TAG. All of them were significantly upregulated at 4 hpi (<xref ref-type="fig" rid="ijms-20-05952-f004">Figure 4</xref>A and <xref rid="ijms-20-05952-t001" ref-type="table">Table 1</xref>). CV-A16-infected cells exhibited a total of 41 perturbed lipids belonging to 10 lipid classes, including CL, FFA, EtherLPC, EtherLPE, EtherPE, LPC, LPE, TAG, PC, and SM. Except for PC, all of them were significantly upregulated in CV-A16 infection. Among the identified lipid classes, FFA, LPC, and TAG showed consistent upregulation in both EV-A71- and CV-A16-infected cells. These included a total of 15 lipids (4 FFAs, 2 LPCs, and 9 TAGs).</p></sec><sec id="sec2dot6-ijms-20-05952"><title>2.6. Antiviral Activites of the Identified Fatty Acids Against EV-A71 and CV-A16</title><p>Fatty acids are known to possess antiviral activities against both DNA and RNA viruses [<xref rid="B19-ijms-20-05952" ref-type="bibr">19</xref>,<xref rid="B20-ijms-20-05952" ref-type="bibr">20</xref>]. We therefore investigated the potential antiviral effects of the identified FFAs against EV-A71 and CV-A16. These four FFAs included arachidonic acid (AA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA). We first confirmed the identities of AA, DHA, DPA, and EPA by matching their retention time (RT) and MS/MS fragmentation patterns with those of the authentic chemical standards. Our box-whisker plots showed that AA, DHA, DPA, and EPA indeed all exhibited significantly (<italic>p</italic> &#x0003c; 0.05) higher levels in both EV-A71- and CV-A16-infected samples at 4 hpi (<xref ref-type="fig" rid="ijms-20-05952-f005">Figure 5</xref>). Then, we treated EV-A71 and CV-A16-infected RD cells with AA, DHA, DPA, or EPA and assessed their anti-enteroviral effects <italic>in vitro</italic>. As shown in <xref ref-type="fig" rid="ijms-20-05952-f006">Figure 6</xref>, AA, DHA, and EPA exhibited significant (<italic>p</italic> &#x0003c; 0.001 to &#x0003c;0.05) antiviral effects against both EV-A71 and CV-A16 with 1&#x02013;2 logs reduction in viral load.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-20-05952"><title>3. Discussion</title><p>EV-A71 and CV-A16 are two of the most common causes of HFMD and repeatedly cause epidemics, especially among children in the Asia&#x02013;Pacific region. While it is known that enteroviruses induce massive remodeling of intracellular membranes during viral replication [<xref rid="B21-ijms-20-05952" ref-type="bibr">21</xref>,<xref rid="B22-ijms-20-05952" ref-type="bibr">22</xref>,<xref rid="B23-ijms-20-05952" ref-type="bibr">23</xref>], data on the cellular lipidomic profiles upon EV-A71 and CV-A16 infection are lacking. In this study, we established an ultra-high performance liquid chromatography (UPLC) MS-based lipidomics approach to characterize the host cell lipid perturbations upon enterovirus infection. Omics-based analytical method assessments and statistical analyses showed that our unbiased lipidomics approach was reliable in identifying significant differences in the host lipid profiles during enterovirus infection. We identified a total of 47 significantly changed lipids that belonged to the phospholipid, glycerolipid, fatty acyls, and sphingolipid categories among EV-A71-infected, CV-A16-infected, and mock-infected samples. These results showed that EV-A71 and CV-A16 infections significantly perturbed a wide range of host lipids.</p><p>Among the significantly changed lipids, four fatty acids, namely, AA, DHA, DPA, and EPA, were upregulated in both EV-A71 and CV-A16-infected samples, indicating their potentially important roles in <italic>Enterovirus</italic> A infections. In corroboration with our findings, a recent report also showed that human rhinovirus A, another important human pathogenic picornavirus, induces substantial fatty acid modifications in human bronchial epithelial cells [<xref rid="B24-ijms-20-05952" ref-type="bibr">24</xref>]. AA, DHA, DPA, and EPA are all polyunsaturated fatty acids (PUFA). AA is an omega-6 PUFA, while DHA, DPA, and EPA are omega-3 PUFAs [<xref rid="B25-ijms-20-05952" ref-type="bibr">25</xref>]. It has been previously shown that PUFA play key roles in inflammatory processes [<xref rid="B9-ijms-20-05952" ref-type="bibr">9</xref>,<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>,<xref rid="B26-ijms-20-05952" ref-type="bibr">26</xref>]. AA is a precursor to pro-inflammatory mediators such as prostaglandins (PG) and leukotrienes (LT), as well as lipoxins, which are endogenous anti-inflammatory, pro-resolving molecules reducing tissue injury and chronic inflammation [<xref rid="B27-ijms-20-05952" ref-type="bibr">27</xref>]. DHA and EPA inhibit lipopolysaccharide-induced and lipopeptide-induced cyclooxygenase-2 expression and thus the inflammatory response in epithelial and dendritic cells [<xref rid="B28-ijms-20-05952" ref-type="bibr">28</xref>,<xref rid="B29-ijms-20-05952" ref-type="bibr">29</xref>]. Moreover, lipids derived from EPA (Resolvin E series) and DHA (Resolvin D series, maresins, and protectins) are involved in the resolution of inflammation and exhibit anti-inflammatory properties [<xref rid="B26-ijms-20-05952" ref-type="bibr">26</xref>,<xref rid="B30-ijms-20-05952" ref-type="bibr">30</xref>]. The omega-3 and omega-6 PUFAs interact in a delicate manner to regulate the inflammatory response. For example, omega-3 PUFAs such as DHA and EPA may serve as competitive substrates for omega-6 PUFA metabolism to decrease AA-derived eicosanoids and their effects on inflammation [<xref rid="B31-ijms-20-05952" ref-type="bibr">31</xref>]. </p><p>In addition to their immunomodulatory roles, the omega-3 and omega-6 PUFAs can also directly regulate virus replication. We previously demonstrated that AA and linoleic acids (LA) could inhibit the replication of coronaviruses including the Middle East respiratory syndrome coronavirus (MERS-CoV) and human coronavirus 229E (HCoV-229E) [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>]. Similarly, the PUFA-derived lipid mediator protectin D1 (PD1) was reported to markedly attenuate influenza virus replication via interference with the virus RNA export machinery [<xref rid="B26-ijms-20-05952" ref-type="bibr">26</xref>]. On the other hand, inhibition of the PUFA synthesis pathway through depleting the delta 6-desaturase enzyme or by treatment with a small-molecule inhibitor impaired hepatitis C virus (HCV) production, indicating that PUFAs could also be required for virion morphogenesis [<xref rid="B32-ijms-20-05952" ref-type="bibr">32</xref>]. </p><p>To investigate the biological relevance of the significantly upregulated expression of PUFAs in the context of enterovirus infection, we evaluated the effects of AA, DHA, DPA, and EPA on the replication of EV-A71 and CV-A16. We showed that three of these four PUFAs (AA, DHA, and EPA) significantly inhibited the replication of both viruses. This corroborated with our previous observation that fatty acids, including AA, possesses antiviral activity against coronaviruses [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>]. Taken together, these results suggested that like coronaviruses, EV-A71 and CV-A16 might modulate specific lipid pathways in the host lipid profile to achieve an intricate homeostasis to facilitate their replication. Excessive exogenous addition of lipids might therefore disrupt this delicate homeostatic state and prevent efficient viral replication. Corroborating with our recent identification of sterol regulatory element-binding proteins (SREBPs) as a broad-spectrum antiviral treatment, precise manipulation of the host lipid profile might therefore be a potential host-targeting antiviral strategy for enterovirus infection [<xref rid="B33-ijms-20-05952" ref-type="bibr">33</xref>]. </p></sec><sec id="sec4-ijms-20-05952"><title>4. Materials and Methods </title><sec id="sec4dot1-ijms-20-05952"><title>4.1. Viruses and Cells</title><p>RD (ATCC, CCL-136) cells were maintained in Dulbecco&#x02019;s modified eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100U/mL penicillin, and 100g/mL streptomycin, and incubated in 5% CO<sub>2</sub> at 37&#x000b0;C. Archived clinical isolates of EV-A71 and CV-A16 isolated from patients with HFMD were available at the Department of Microbiology, The University of Hong Kong. The viruses were cultured in RD cells in serum-free DMEM supplemented with 100 U/mL penicillin and 100 g/mL streptomycin. The supernatants were harvested when cytopathic effects (CPE) were observed and centrifuged to generate the viral stocks. The virus stocks were titrated by plaque assay on VeroE6 cells and stored at &#x02212;80&#x000b0;C, as previously described. Briefly, confluent VeroE6 cells were infected with 10-fold serial viral dilutions. The cells were incubated with diluted viruses at 37 &#x000b0;C for 1 h and subsequently overlaid with 1% low-melting-point agarose (Promega, Madison, WI, USA). The cells were fixed with 4% formaldehyde as the plaques were observed and then stained with 0.2% crystal violet. All experiments involving live EV-A71 and CV-A16 followed the approved standard operating procedures of the biosafety level 2 facility at the Department of Microbiology, The University of Hong Kong, as previously described.</p></sec><sec id="sec4dot2-ijms-20-05952"><title>4.2. Chemical Reagents and Standards</title><p>The chemical reagents and standards for HPLC were prepared as previously described [<xref rid="B15-ijms-20-05952" ref-type="bibr">15</xref>]. Briefly, HPLC-grade methanol, acetonitrile, chloroform, and isopropanol were purchased from Merck (Darmstadt, Germany). A Milli-Q water purification system (Millipore, Burlington, MA, USA) was used to prepare HPLC-grade water. Analytical grade formic acid, ammonium formate, and commercial standards used for biomarker identification were purchased from Sigma-Aldrich (St. Louis, MO, USA). Internal standards (IS) including Arachidonic acid-d8, Platelet-activating factor C-16-d4 (PAF C-16-d4), 22:1 Cholesterol Ester, PE (17:0/17:0), PG (17:0/17:0), PC(17:0/0:0), C17 Sphingosine, C17 Ceramide, SM (d18:1/17:0), PC (12:0/13:0), Cholesterol (d7), TG (17:0/17:1/17:0) d5, DG (12:0/12:0/0:0), DG (18:1/2:0/0:0), and PE (17:1/0:0) were purchased from Cayman Chemical (Ann Arbor, MI, USA) and Avanti Polar Lipids, Inc (Alabaster, AL, USA).</p></sec><sec id="sec4dot3-ijms-20-05952"><title>4.3. Lipid Treatment of EV-A71-Infected and CV-A16-Infected RD Cells</title><p>Lipid treatments of virus-infected cells were performed, as previously described, with modifications [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>]. Briefly, RD cells were seeded into 96-well plates to reach 90% confluency for infection. The cells were pre-incubated with lipid-supplemented medium at the following concentrations for 2 h: AA and DPA = 100 &#x000b5;M, DHA = 50 &#x000b5;M, and EPA = 60 &#x000b5;M. Then, the cells were infected with either EV-A71 or CV-A16 (multiplicity of infection, MOI = 10.0). At 1 hpi, the cells were washed three times with DMEM. The cells were replenished with lipid-supplemented medium for 4 h of incubation. The cell lysates were then collected for qRT-PCR.</p></sec><sec id="sec4dot4-ijms-20-05952"><title>4.4. Lipid Extraction for Lipidomics Profiling</title><p>Confluent RD cells were infected with EV-A71 or CV-A16 (MOI = 10) and incubated in DMEM medium. Mock-infected RD cells were used as controls. The cells (four biological replicates per group) were collected for cellular lipid extraction at 4 hpi. Lipid extraction was performed for liquid chromatography-mass spectrometry (LC-MS) analysis according to a previously described protocol with slight modifications [<xref rid="B34-ijms-20-05952" ref-type="bibr">34</xref>]. Briefly, 550 &#x000b5;L of ice-cold 150 mM ammonium bicarbonate solution was added to dissociate cells and 50 &#x000b5;L of cell suspension was used for DNA extraction for normalization [<xref rid="B35-ijms-20-05952" ref-type="bibr">35</xref>]. A total of 250 &#x000b5;L of methanol containing IS and butylated hydroxytoluene (BHT) was added to the wells. Then, 2 mL of chloroform/methanol (v/v 2:1) was added, followed by vortexing and centrifugation at 4500 rpm for 10 min at 4 &#x000b0;C. The bottom phase was transferred to glass vials and dried in a Labconco Centrivap cold trap concentrator for storage at &#x02212;80 &#x025e6;C. The dried samples were reconstituted in 25 &#x000b5;L of chloroform-methanol (1:1, v/v) and diluted to 1:10 of the original concentration of cell lysate in 225 &#x000b5;L IPA-ACN-water (2:1:1, v/v/v) for LC-MS analysis [<xref rid="B36-ijms-20-05952" ref-type="bibr">36</xref>]. Inactivation of virus infectivity was confirmed before further processing, as previously described, with some modifications [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>,<xref rid="B33-ijms-20-05952" ref-type="bibr">33</xref>].</p></sec><sec id="sec4dot5-ijms-20-05952"><title>4.5. Ultra-High Performance Liquid Chromatography-Electrospray Ionization-Quadrupole-Time of Flight-Mass Spectrometry (UPLC-ESI-Q-TOF-MS) Analysis</title><p>UPLC-ESI-Q-TOF-MS analysis was performed, as previously described, with slight modifications [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>]. Briefly, the lipid extract was analyzed using an Acquity UPLC system coupled to a Synapt G2-Si High Definition Mass Spectrometry (HDMS) system (Waters Corp., Milford, MA, USA). The chromatography was performed on a Waters ACQUITY CSH C18 column (100 &#x000d7; 2.1 mm; 1.7 &#x000b5;m) coupled to an Acquity CSH C18 VanGuard pre-column (5 &#x000d7; 2.1 mm; 1.7 &#x000b5;m) (Waters; Milford, MA, USA). The mobile phase A was 60:40 acetonitrile:water (v/v) with 10 mM ammonium formate and 0.1% formic acid. The mobile phase B for positive mode was 90:10 isopropanol:acetonitrile (v/v) with 10 mM ammonium formate and 0.1% formic acid. The mobile phase B for negative mode was 90:10 isopropanol:acetonitrile (v/v) with 10 mM ammonium acetate [<xref rid="B37-ijms-20-05952" ref-type="bibr">37</xref>]. Gradient elution applied for UPLC-MS analysis was described in <xref ref-type="app" rid="app1-ijms-20-05952">Table S3</xref>. The column and autosampler temperature were maintained at 55 &#x000b0;C and 4 &#x000b0;C, respectively. The injection volume was 7 &#x000b5;L. The mass spectral data were acquired in both positive and negative modes. The capillary voltage was maintained at 2.5kV (positive mode) and 2.0 kV (negative mode). The sampling cone voltage and source offset were maintained at 30 V and 60 V, respectively. Nitrogen was used as desolvation gas at a flow rate of 800 L/h. The source and desolvation temperatures were maintained at 120 &#x000b0;C and 400 &#x000b0;C, respectively. Mass spectra were acquired over the m/z range of 100&#x02013;1500. The SYNAPT G2-Si HDMS system was calibrated using sodium formate clusters and operated in sensitivity mode. Leucine enkephalin was used as a lock mass for all experiments. MS/MS acquisition was operated in the same parameters as in MS acquisition. Collision energy was applied in the range of 30&#x02013;45 eV for fragmentation to allow putative identification and structural elucidation of the significant lipids.</p></sec><sec id="sec4dot6-ijms-20-05952"><title>4.6. Analytical Method Assessment</title><p>To investigate the lipid detection and extraction capacity of the current method, a total of 15 lipid internal standards were applied for sample preparation and LC-MS analysis for monitoring the lipids coverage and extraction efficiency. Additionally, to check the stability of the LC-MS system during the analytical batch, QC samples were injected at the beginning of the run and after every six samples for monitoring the system variation. QC samples were prepared by pooling equal aliquots of each sample in the current study [<xref rid="B38-ijms-20-05952" ref-type="bibr">38</xref>].</p></sec><sec id="sec4dot7-ijms-20-05952"><title>4.7. Data Processing and Statistical Analysis</title><p>Acquisition of the raw data was performed using MassLynx software version 4.1 (Waters Corp., MA, USA) and raw data were converted into the Analysis Base File (ABF) format by the Reifycs ABF Converter software (<uri xlink:href="https://www.reifycs.com/AbfConverter/">https://www.reifycs.com/AbfConverter/</uri>) [<xref rid="B16-ijms-20-05952" ref-type="bibr">16</xref>]. The ABF data were then processed to generate a usable data matrix including annotation lipid name, accurate mass, retention time, and the corresponding intensity of unique MS features by the MS-DIAL software (<uri xlink:href="http://prime.psc.riken.jp/Metabolomics_Software/MS-DIAL/">http://prime.psc.riken.jp/Metabolomics_Software/MS-DIAL/</uri>) [<xref rid="B16-ijms-20-05952" ref-type="bibr">16</xref>,<xref rid="B39-ijms-20-05952" ref-type="bibr">39</xref>]. The data matrix was then exported as a .csv file for statistical analysis. MetaboAnalyst 3.0 (<uri xlink:href="http://www.metaboanalyst.ca">http://www.metaboanalyst.ca</uri>) and SIMCA-P V12.0 (Umetrics, Ume&#x000e5;, Sweden) were used for univariate and multivariate analysis, respectively [<xref rid="B40-ijms-20-05952" ref-type="bibr">40</xref>]. For univariate analysis, the statistical significance of the features was determined by comparing the mock-infected and virus-infected groups using the Student&#x02019;s t-test and the fold changes. Adjust <italic>p</italic>-value &#x0003c; 0.05, fold change &#x0003e;1.25 or &#x0003c;0.8 were used as the criteria for selecting significant features. For multivariate analysis, the features were first subjected to Pareto scaling, followed by orthogonal partial least squares discriminant analysis (OPLS-DA) to find important variables with discriminative power. Variable importance in projection (VIP) score &#x0003e;1 was used as a criterion for significant lipid features selection. The R2X/R2Y and Q2, which represented the X/Y variables explanation rate and the predicted ability of the OPLS-DA model, respectively, were calculated using the SIMCA-P software [<xref rid="B41-ijms-20-05952" ref-type="bibr">41</xref>].</p></sec><sec id="sec4dot8-ijms-20-05952"><title>4.8. Lipids Identification</title><p>The identification of lipids was performed as previously described [<xref rid="B13-ijms-20-05952" ref-type="bibr">13</xref>]. Briefly, MS/MS fragmentation was performed on the significant features with high abundances. The significant features were identified by searching accurate MS and MS/MS fragmentation pattern data in the MS-DIAL internal lipid database [<xref rid="B39-ijms-20-05952" ref-type="bibr">39</xref>], MassBank of North America (MoNA, <uri xlink:href="http://mona.fiehnlab.ucdavis.edu/">http://mona.fiehnlab.ucdavis.edu/</uri>), METLIN database (<uri xlink:href="http://metlin.scripps.edu/">http://metlin.scripps.edu/</uri>), and LIPID MAPS (<uri xlink:href="http://www.lipidmaps.org/">http://www.lipidmaps.org/</uri>). For confirmation of lipid identity using authentic chemical standards, the MS/MS fragmentation patterns of the chemical standards were compared with those of the candidate lipids measured under the same LC-MS condition.</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-20-05952"><title>5. Conclusions</title><p>In summary, we established and exploited a reliable unbiased lipidomic approach to characterize the host lipidomic profile changes upon EV-A71 and CV-A16 infections. Our finding of significantly upregulated expression of these PUFAs in EV-A71 and CV-A16 infections provided novel understanding into the pathogenesis and host-targeting antiviral strategies for enterovirus infections.</p></sec></body><back><app-group><app id="app1-ijms-20-05952"><title>Supplementary Materials</title><p>Supplementary materials can be found at <uri xlink:href="https://www.mdpi.com/1422-0067/20/23/5952/s1">https://www.mdpi.com/1422-0067/20/23/5952/s1</uri>.</p><supplementary-material content-type="local-data" id="ijms-20-05952-s001"><media xlink:href="ijms-20-05952-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>B.Y., Z.Z., H.C., J.F.-W.C and K.-Y.Y. conceived and designed the experiments; B.Y., Z.Z., G.C., J.O.-L.T., P.-M.L., and K.-H.S. performed the experiments; B.Y., Z.Z., H.C., J.O.-L.T., S.Y., C.C.-Y.Y., F.Y., R.Y.-T.K., K.-H.S., S.K.-P.L., J.F.-W.C. and K.-Y.Y. analyzed the data; S.Y., C.C.-Y.Y., R.Y.-T.K., S.K.-P.L., J.-F.W.C. and K.-Y.Y. contributed reagents/materials/analysis tools; B.Y., Z.Z., H.C., J.F.-W.C. and K.-Y.Y. wrote the paper, all authors revised and approved the final version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was partly supported by the donations of Michael Seak-Kan Tong, Respiratory Virus Research Foundation, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Ms. Marina Man-Wai Lee, Chan Yin Chuen Memorial Charitable Foundation, and the Hong Kong Hainan Commercial Association South China Microbiology Research Fund; and funding from the Health and Medical Research Fund (HKM-15-M02, HKM-15-M04, HKM-15-M05, and HKM-15-M11) of the Food and Health Bureau, Hong Kong Special Administrative Region Government; and the Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the Ministry of Education of China. The sponsors had no role in the design and conduct of the study, in the collection, analysis and interpretation of data, or in the preparation, review or approval of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declared no conflict of interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-ijms-20-05952"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>S.S.</given-names></name><name><surname>Yip</surname><given-names>C.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Human enterovirus 71 and hand, foot and mouth disease</article-title><source>Epidemiol Infect.</source><year>2010</year><volume>138</volume><fpage>1071</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1017/S0950268809991555</pub-id><?supplied-pmid 20056019?><pub-id pub-id-type="pmid">20056019</pub-id></element-citation></ref><ref id="B2-ijms-20-05952"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>W.</given-names></name><name><surname>Liao</surname><given-names>Q.</given-names></name><name><surname>Viboud</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.T.</given-names></name><name><surname>Chang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Fang</surname><given-names>V.J.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Hand, foot, and mouth disease in China, 2008-12: an epidemiological study</article-title><source>Lancet Infect. Dis</source><year>2014</year><volume>14</volume><fpage>308</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70342-6</pub-id><pub-id pub-id-type="pmid">24485991</pub-id></element-citation></ref><ref id="B3-ijms-20-05952"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L.Y.</given-names></name><name><surname>Lin</surname><given-names>T.Y.</given-names></name><name><surname>Hsu</surname><given-names>K.H.</given-names></name><name><surname>Huang</surname><given-names>Y.C.</given-names></name><name><surname>Lin</surname><given-names>K.L.</given-names></name><name><surname>Hsueh</surname><given-names>C.</given-names></name><name><surname>Shih</surname><given-names>S.R.</given-names></name><name><surname>Ning</surname><given-names>H.C.</given-names></name><name><surname>Hwang</surname><given-names>M.S.</given-names></name><name><surname>Wang</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>1682</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)04434-7</pub-id><pub-id pub-id-type="pmid">10568570</pub-id></element-citation></ref><ref id="B4-ijms-20-05952"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>C.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Human enterovirus 71 epidemics: what&#x02019;s next?</article-title><source>Emerg Health Threats J.</source><year>2013</year><volume>6</volume><fpage>19780</fpage><pub-id pub-id-type="doi">10.3402/ehtj.v6i0.19780</pub-id><?supplied-pmid 24119538?><pub-id pub-id-type="pmid">24119538</pub-id></element-citation></ref><ref id="B5-ijms-20-05952"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>M.H.</given-names></name><name><surname>Wong</surname><given-names>S.C.</given-names></name><name><surname>Lewthwaite</surname><given-names>P.</given-names></name><name><surname>Cardosa</surname><given-names>M.J.</given-names></name><name><surname>Solomon</surname><given-names>T.</given-names></name></person-group><article-title>Clinical features, diagnosis, and management of enterovirus 71</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70209-X</pub-id><pub-id pub-id-type="pmid">20965438</pub-id></element-citation></ref><ref id="B6-ijms-20-05952"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taube</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>M.X.</given-names></name><name><surname>Wobus</surname><given-names>C.E.</given-names></name></person-group><article-title>Glycosphingolipids as Receptors for Non-Enveloped Viruses</article-title><source>Viruses-Basel</source><year>2010</year><volume>2</volume><fpage>1011</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.3390/v2041011</pub-id></element-citation></ref><ref id="B7-ijms-20-05952"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chazal</surname><given-names>N.</given-names></name><name><surname>Gerlier</surname><given-names>D.</given-names></name></person-group><article-title>Virus entry, assembly, budding, and membrane rafts</article-title><source>Microbiol Mol. Biol Rev.</source><year>2003</year><volume>67</volume><fpage>226</fpage><lpage>237</lpage><comment>table of contents</comment><pub-id pub-id-type="doi">10.1128/MMBR.67.2.226-237.2003</pub-id><pub-id pub-id-type="pmid">12794191</pub-id></element-citation></ref><ref id="B8-ijms-20-05952"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>P.D.</given-names></name><name><surname>Strating</surname><given-names>J.R.P.M.</given-names></name><name><surname>van Kuppeveld</surname><given-names>F.J.M.</given-names></name></person-group><article-title>Building Viral Replication Organelles: Close Encounters of the Membrane Types</article-title><source>Plos Pathogens</source><year>2016</year><volume>12</volume><pub-id pub-id-type="doi">10.1371/journal.ppat.1005912</pub-id></element-citation></ref><ref id="B9-ijms-20-05952"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>N.Y.</given-names></name><name><surname>Ilnytska</surname><given-names>O.</given-names></name><name><surname>Belov</surname><given-names>G.</given-names></name><name><surname>Santiana</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>Y.H.</given-names></name><name><surname>Takvorian</surname><given-names>P.M.</given-names></name><name><surname>Pau</surname><given-names>C.</given-names></name><name><surname>van der Schaar</surname><given-names>H.</given-names></name><name><surname>Kaushik-Basu</surname><given-names>N.</given-names></name><name><surname>Balla</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Viral Reorganization of the Secretory Pathway Generates Distinct Organelles for RNA Replication</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>799</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.050</pub-id><pub-id pub-id-type="pmid">20510927</pub-id></element-citation></ref><ref id="B10-ijms-20-05952"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>A.</given-names></name><name><surname>Ablan</surname><given-names>S.D.</given-names></name><name><surname>Lockett</surname><given-names>S.J.</given-names></name><name><surname>Nagashima</surname><given-names>K.</given-names></name><name><surname>Freed</surname><given-names>E.O.</given-names></name></person-group><article-title>Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane</article-title><source>Proc. Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>14889</fpage><lpage>14894</lpage><pub-id pub-id-type="doi">10.1073/pnas.0405596101</pub-id><pub-id pub-id-type="pmid">15465916</pub-id></element-citation></ref><ref id="B11-ijms-20-05952"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Pekosz</surname><given-names>A.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name></person-group><article-title>Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins</article-title><source>J. Virol</source><year>2000</year><volume>74</volume><fpage>4634</fpage><lpage>4644</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.10.4634-4644.2000</pub-id><?supplied-pmid 10775599?><pub-id pub-id-type="pmid">10775599</pub-id></element-citation></ref><ref id="B12-ijms-20-05952"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>C.</given-names></name><name><surname>Hardt</surname><given-names>M.</given-names></name><name><surname>Schwudke</surname><given-names>D.</given-names></name><name><surname>Neuman</surname><given-names>B.W.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>Inhibition of Cytosolic Phospholipase A2alpha Impairs an Early Step of Coronavirus Replication in Cell Culture</article-title><source>J. Virol</source><year>2018</year><volume>92</volume><pub-id pub-id-type="doi">10.1128/JVI.01463-17</pub-id></element-citation></ref><ref id="B13-ijms-20-05952"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Sze</surname><given-names>K.H.</given-names></name><name><surname>Lai</surname><given-names>P.M.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Shuai</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication</article-title><source>Viruses</source><year>2019</year><volume>11</volume><pub-id pub-id-type="doi">10.3390/v11010073</pub-id><?supplied-pmid 30654597?><pub-id pub-id-type="pmid">30654597</pub-id></element-citation></ref><ref id="B14-ijms-20-05952"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauling</surname><given-names>J.K.</given-names></name><name><surname>Hermansson</surname><given-names>M.</given-names></name><name><surname>Hartler</surname><given-names>J.</given-names></name><name><surname>Christiansen</surname><given-names>K.</given-names></name><name><surname>Gallego</surname><given-names>S.F.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Ahrends</surname><given-names>R.</given-names></name><name><surname>Ejsing</surname><given-names>C.S.</given-names></name></person-group><article-title>Proposal for a common nomenclature for fragment ions in mass spectra of lipids</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0188394</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0188394</pub-id><?supplied-pmid 29161304?><pub-id pub-id-type="pmid">29161304</pub-id></element-citation></ref><ref id="B15-ijms-20-05952"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>J.</given-names></name><name><surname>Bi</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>UHPLC-LTQ-Orbitrap MS combined with spike-in method for plasma metabonomics analysis of acute myocardial ischemia rats and pretreatment effect of Danqi Tongmai tablet</article-title><source>Mol. Biosyst</source><year>2015</year><volume>11</volume><fpage>486</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1039/C4MB00529E</pub-id><?supplied-pmid 25418780?><pub-id pub-id-type="pmid">25418780</pub-id></element-citation></ref><ref id="B16-ijms-20-05952"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsugawa</surname><given-names>H.</given-names></name><name><surname>Cajka</surname><given-names>T.</given-names></name><name><surname>Kind</surname><given-names>T.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Higgins</surname><given-names>B.</given-names></name><name><surname>Ikeda</surname><given-names>K.</given-names></name><name><surname>Kanazawa</surname><given-names>M.</given-names></name><name><surname>VanderGheynst</surname><given-names>J.</given-names></name><name><surname>Fiehn</surname><given-names>O.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name></person-group><article-title>MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis</article-title><source>Nat. Methods</source><year>2015</year><volume>12</volume><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3393</pub-id><pub-id pub-id-type="pmid">25938372</pub-id></element-citation></ref><ref id="B17-ijms-20-05952"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahy</surname><given-names>E.</given-names></name><name><surname>Cotter</surname><given-names>D.</given-names></name><name><surname>Sud</surname><given-names>M.</given-names></name><name><surname>Subramaniam</surname><given-names>S.</given-names></name></person-group><article-title>Lipid classification, structures and tools</article-title><source>Biochim Biophys Acta</source><year>2011</year><volume>1811</volume><fpage>637</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2011.06.009</pub-id><pub-id pub-id-type="pmid">21704189</pub-id></element-citation></ref><ref id="B18-ijms-20-05952"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebisch</surname><given-names>G.</given-names></name><name><surname>Vizcaino</surname><given-names>J.A.</given-names></name><name><surname>Kofeler</surname><given-names>H.</given-names></name><name><surname>Trotzmuller</surname><given-names>M.</given-names></name><name><surname>Griffiths</surname><given-names>W.J.</given-names></name><name><surname>Schmitz</surname><given-names>G.</given-names></name><name><surname>Spener</surname><given-names>F.</given-names></name><name><surname>Wakelam</surname><given-names>M.J.</given-names></name></person-group><article-title>Shorthand notation for lipid structures derived from mass spectrometry</article-title><source>J. Lipid Res.</source><year>2013</year><volume>54</volume><fpage>1523</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1194/jlr.M033506</pub-id><pub-id pub-id-type="pmid">23549332</pub-id></element-citation></ref><ref id="B19-ijms-20-05952"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thormar</surname><given-names>H.</given-names></name><name><surname>Isaacs</surname><given-names>C.E.</given-names></name><name><surname>Brown</surname><given-names>H.R.</given-names></name><name><surname>Barshatzky</surname><given-names>M.R.</given-names></name><name><surname>Pessolano</surname><given-names>T.</given-names></name></person-group><article-title>Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides</article-title><source>Antimicrob Agents Chemother</source><year>1987</year><volume>31</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.1.27</pub-id><pub-id pub-id-type="pmid">3032090</pub-id></element-citation></ref><ref id="B20-ijms-20-05952"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.J.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Hao</surname><given-names>X.A.</given-names></name><name><surname>Wu</surname><given-names>Y.F.</given-names></name></person-group><article-title>Application of fatty acids as antiviral agents against tobacco mosaic virus</article-title><source>Pesticide Biochemistry and Physiology</source><year>2017</year><volume>139</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.pestbp.2017.05.005</pub-id><pub-id pub-id-type="pmid">28595927</pub-id></element-citation></ref><ref id="B21-ijms-20-05952"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bienz</surname><given-names>K.</given-names></name><name><surname>Egger</surname><given-names>D.</given-names></name><name><surname>Pfister</surname><given-names>T.</given-names></name><name><surname>Troxler</surname><given-names>M.</given-names></name></person-group><article-title>Structural and functional characterization of the poliovirus replication complex</article-title><source>J. Virol</source><year>1992</year><volume>66</volume><fpage>2740</fpage><lpage>2747</lpage><?supplied-pmid 1313898?><pub-id pub-id-type="pmid">1313898</pub-id></element-citation></ref><ref id="B22-ijms-20-05952"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlegel</surname><given-names>A.</given-names></name><name><surname>Giddings</surname><given-names>T.H.</given-names><suffix>Jr.</suffix></name><name><surname>Ladinsky</surname><given-names>M.S.</given-names></name><name><surname>Kirkegaard</surname><given-names>K.</given-names></name></person-group><article-title>Cellular origin and ultrastructure of membranes induced during poliovirus infection</article-title><source>J. Virol</source><year>1996</year><volume>70</volume><fpage>6576</fpage><lpage>6588</lpage><?supplied-pmid 8794292?><pub-id pub-id-type="pmid">8794292</pub-id></element-citation></ref><ref id="B23-ijms-20-05952"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suhy</surname><given-names>D.A.</given-names></name><name><surname>Giddings</surname><given-names>T.H.</given-names><suffix>Jr.</suffix></name><name><surname>Kirkegaard</surname><given-names>K.</given-names></name></person-group><article-title>Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles</article-title><source>J. Virol</source><year>2000</year><volume>74</volume><fpage>8953</fpage><lpage>8965</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.19.8953-8965.2000</pub-id><?supplied-pmid 10982339?><pub-id pub-id-type="pmid">10982339</pub-id></element-citation></ref><ref id="B24-ijms-20-05952"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A.</given-names></name><name><surname>Guedan</surname><given-names>A.</given-names></name><name><surname>Mousnier</surname><given-names>A.</given-names></name><name><surname>Swieboda</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Horkai</surname><given-names>D.</given-names></name><name><surname>Le Novere</surname><given-names>N.</given-names></name><name><surname>Solari</surname><given-names>R.</given-names></name><name><surname>Wakelam</surname><given-names>M.J.O.</given-names></name></person-group><article-title>Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets</article-title><source>J. Lipid Res.</source><year>2018</year><volume>59</volume><fpage>1671</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1194/jlr.M085910</pub-id><?supplied-pmid 29946055?><pub-id pub-id-type="pmid">29946055</pub-id></element-citation></ref><ref id="B25-ijms-20-05952"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratnayake</surname><given-names>W.M.</given-names></name><name><surname>Galli</surname><given-names>C.</given-names></name></person-group><article-title>Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper</article-title><source>Ann. Nutr. Metab.</source><year>2009</year><volume>55</volume><fpage>8</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1159/000228994</pub-id><pub-id pub-id-type="pmid">19752534</pub-id></element-citation></ref><ref id="B26-ijms-20-05952"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>M.</given-names></name><name><surname>Kuba</surname><given-names>K.</given-names></name><name><surname>Ichikawa</surname><given-names>A.</given-names></name><name><surname>Nakayama</surname><given-names>M.</given-names></name><name><surname>Katahira</surname><given-names>J.</given-names></name><name><surname>Iwamoto</surname><given-names>R.</given-names></name><name><surname>Watanebe</surname><given-names>T.</given-names></name><name><surname>Sakabe</surname><given-names>S.</given-names></name><name><surname>Daidoji</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The Lipid Mediator Protectin D1 Inhibits Influenza Virus Replication and Improves Severe Influenza</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>112</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.027</pub-id><pub-id pub-id-type="pmid">23477864</pub-id></element-citation></ref><ref id="B27-ijms-20-05952"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>G.</given-names></name><name><surname>Ecker</surname><given-names>J.</given-names></name></person-group><article-title>The opposing effects of n-3 and n-6 fatty acids</article-title><source>Prog Lipid Res.</source><year>2008</year><volume>47</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2007.12.004</pub-id><pub-id pub-id-type="pmid">18198131</pub-id></element-citation></ref><ref id="B28-ijms-20-05952"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Plakidas</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>W.H.</given-names></name><name><surname>Heikkinen</surname><given-names>A.</given-names></name><name><surname>Chanmugam</surname><given-names>P.</given-names></name><name><surname>Bray</surname><given-names>G.</given-names></name><name><surname>Hwang</surname><given-names>D.H.</given-names></name></person-group><article-title>Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids</article-title><source>J. Lipid Res.</source><year>2003</year><volume>44</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1194/jlr.M200361-JLR200</pub-id><pub-id pub-id-type="pmid">12562875</pub-id></element-citation></ref><ref id="B29-ijms-20-05952"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>A.</given-names></name><name><surname>Mbodji</surname><given-names>K.</given-names></name><name><surname>Hassan</surname><given-names>A.</given-names></name><name><surname>Aziz</surname><given-names>M.</given-names></name><name><surname>Boukhettala</surname><given-names>N.</given-names></name><name><surname>Coeffier</surname><given-names>M.</given-names></name><name><surname>Savoye</surname><given-names>G.</given-names></name><name><surname>Dechelotte</surname><given-names>P.</given-names></name><name><surname>Marion-Letellier</surname><given-names>R.</given-names></name></person-group><article-title>Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium</article-title><source>Clin. Nutr</source><year>2011</year><volume>30</volume><fpage>678</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2011.05.002</pub-id><pub-id pub-id-type="pmid">21632157</pub-id></element-citation></ref><ref id="B30-ijms-20-05952"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Tjonahen</surname><given-names>E.</given-names></name><name><surname>Glickman</surname><given-names>J.N.</given-names></name><name><surname>Petasis</surname><given-names>N.A.</given-names></name><name><surname>Blumberg</surname><given-names>R.S.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis</article-title><source>Proc. Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>7671</fpage><lpage>7676</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409271102</pub-id><pub-id pub-id-type="pmid">15890784</pub-id></element-citation></ref><ref id="B31-ijms-20-05952"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marion-Letellier</surname><given-names>R.</given-names></name><name><surname>Savoye</surname><given-names>G.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name></person-group><article-title>Polyunsaturated fatty acids and inflammation</article-title><source>IUBMB Life</source><year>2015</year><volume>67</volume><fpage>659</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/iub.1428</pub-id><pub-id pub-id-type="pmid">26397837</pub-id></element-citation></ref><ref id="B32-ijms-20-05952"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>S.</given-names></name><name><surname>Krajewski</surname><given-names>M.</given-names></name><name><surname>Scherer</surname><given-names>C.</given-names></name><name><surname>Scholz</surname><given-names>V.</given-names></name><name><surname>Mordhorst</surname><given-names>V.</given-names></name><name><surname>Truschow</surname><given-names>P.</given-names></name><name><surname>Schobel</surname><given-names>A.</given-names></name><name><surname>Reimer</surname><given-names>R.</given-names></name><name><surname>Schwudke</surname><given-names>D.</given-names></name><name><surname>Herker</surname><given-names>E.</given-names></name></person-group><article-title>Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication</article-title><source>Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids</source><year>2018</year><volume>1863</volume><fpage>1041</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2018.06.002</pub-id><?supplied-pmid 29885363?><pub-id pub-id-type="pmid">29885363</pub-id></element-citation></ref><ref id="B33-ijms-20-05952"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Ye</surname><given-names>Z.W.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Lai</surname><given-names>P.M.</given-names></name><name><surname>Tee</surname><given-names>K.M.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><etal/></person-group><article-title>SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target</article-title><source>Nat. Commun</source><year>2019</year><volume>10</volume><fpage>120</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-08015-x</pub-id><pub-id pub-id-type="pmid">30631056</pub-id></element-citation></ref><ref id="B34-ijms-20-05952"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnum-Johnson</surname><given-names>K.E.</given-names></name><name><surname>Kyle</surname><given-names>J.E.</given-names></name><name><surname>Eisfeld</surname><given-names>A.J.</given-names></name><name><surname>Casey</surname><given-names>C.P.</given-names></name><name><surname>Stratton</surname><given-names>K.G.</given-names></name><name><surname>Gonzalez</surname><given-names>J.F.</given-names></name><name><surname>Habyarimana</surname><given-names>F.</given-names></name><name><surname>Negretti</surname><given-names>N.M.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Chauhan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling</article-title><source>Analyst</source><year>2017</year><volume>142</volume><fpage>442</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1039/C6AN02486F</pub-id><?supplied-pmid 28091625?><pub-id pub-id-type="pmid">28091625</pub-id></element-citation></ref><ref id="B35-ijms-20-05952"><label>35.</label><element-citation publication-type="journal"><source>Measurement of DNA concentration as a normalization strategy for metabolomic data from adherent cell lines</source><person-group person-group-type="editor"><name><surname>Silva</surname><given-names>L.P.</given-names></name><name><surname>Lorenzi</surname><given-names>P.L.</given-names></name><name><surname>Purwaha</surname><given-names>P.</given-names></name><name><surname>Yong</surname><given-names>V.</given-names></name><name><surname>Hawke</surname><given-names>D.H.</given-names></name><name><surname>Weinstein</surname><given-names>J.N.</given-names></name></person-group><year>2013</year><volume>Volume 85</volume><fpage>9536</fpage><lpage>9542</lpage></element-citation></ref><ref id="B36-ijms-20-05952"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damen</surname><given-names>C.W.</given-names></name><name><surname>Isaac</surname><given-names>G.</given-names></name><name><surname>Langridge</surname><given-names>J.</given-names></name><name><surname>Hankemeier</surname><given-names>T.</given-names></name><name><surname>Vreeken</surname><given-names>R.J.</given-names></name></person-group><article-title>Enhanced lipid isomer separation in human plasma using reversed-phase UPLC with ion-mobility/high-resolution MS detection</article-title><source>J. Lipid Res.</source><year>2014</year><volume>55</volume><fpage>1772</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1194/jlr.D047795</pub-id><pub-id pub-id-type="pmid">24891331</pub-id></element-citation></ref><ref id="B37-ijms-20-05952"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cajka</surname><given-names>T.</given-names></name><name><surname>Fiehn</surname><given-names>O.</given-names></name></person-group><article-title>Increasing lipidomic coverage by selecting optimal mobile-phase modifiers in LC&#x02013;MS of blood plasma</article-title><source>Metabolomics</source><year>2016</year><volume>12</volume><pub-id pub-id-type="doi">10.1007/s11306-015-0929-x</pub-id></element-citation></ref><ref id="B38-ijms-20-05952"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>W.B.</given-names></name><name><surname>Broadhurst</surname><given-names>D.</given-names></name><name><surname>Begley</surname><given-names>P.</given-names></name><name><surname>Zelena</surname><given-names>E.</given-names></name><name><surname>Francis-McIntyre</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>N.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Knowles</surname><given-names>J.D.</given-names></name><name><surname>Halsall</surname><given-names>A.</given-names></name><name><surname>Haselden</surname><given-names>J.N.</given-names></name><etal/></person-group><article-title>Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry</article-title><source>Nat. Protoc.</source><year>2011</year><volume>6</volume><fpage>1060</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1038/nprot.2011.335</pub-id><pub-id pub-id-type="pmid">21720319</pub-id></element-citation></ref><ref id="B39-ijms-20-05952"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kind</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>K.H.</given-names></name><name><surname>Lee</surname><given-names>D.Y.</given-names></name><name><surname>DeFelice</surname><given-names>B.</given-names></name><name><surname>Meissen</surname><given-names>J.K.</given-names></name><name><surname>Fiehn</surname><given-names>O.</given-names></name></person-group><article-title>LipidBlast in silico tandem mass spectrometry database for lipid identification</article-title><source>Nat. Methods</source><year>2013</year><volume>10</volume><fpage>755</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2551</pub-id><pub-id pub-id-type="pmid">23817071</pub-id></element-citation></ref><ref id="B40-ijms-20-05952"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Sinelnikov</surname><given-names>I.V.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Wishart</surname><given-names>D.S.</given-names></name></person-group><article-title>MetaboAnalyst 3.0--making metabolomics more meaningful</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>W251</fpage><lpage>W257</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv380</pub-id><pub-id pub-id-type="pmid">25897128</pub-id></element-citation></ref><ref id="B41-ijms-20-05952"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galindo-Prieto</surname><given-names>B.</given-names></name><name><surname>Eriksson</surname><given-names>L.</given-names></name><name><surname>Trygg</surname><given-names>J.</given-names></name></person-group><article-title>Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS)</article-title><source>J. Chem.</source><year>2014</year><volume>28</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1002/cem.2627</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-20-05952-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Partial least squares discriminant analysis (PLS-DA) score plots in the (<bold>A</bold>) negative and (<bold>B</bold>) positive modes showing the distribution of lipids in RD cells infected with EV-A71, CV-A16, or mock infection. Abbreviations: CA, CV-A16-infected cells; EV, EV-A71-infected cells; Mock, mock-infected cells; 4h, 4 hours post-infection.</p></caption><graphic xlink:href="ijms-20-05952-g001"/></fig><fig id="ijms-20-05952-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Hierarchical clustering analysis generated by MetaboAnalyst based on the all lipid features list in the (<bold>A</bold>) negative and (<bold>B</bold>) positive modes. Each bar represented a lipid feature colored in its average intensity on a normalized scale from blue (decreased) to red (increased). The dendrograms at the top were constructed based on the lipid intensity (similarity measure using Euclidean and Ward clustering algorithm). Abbreviations: CA-4h, CV-A16-infected samples harvested at 4 hours post-infection; EV-4h, EV-A71-infected samples harvested at 4 hours post-infection; Mock-4h, mock-infected samples harvested at 4 hours post-infection.</p></caption><graphic xlink:href="ijms-20-05952-g002"/></fig><fig id="ijms-20-05952-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>(<bold>A</bold>) Pie chart showing the 11 lipid classes of the 47 significantly changed lipids upon enterovirus infection. (<bold>B</bold>) Venn diagram demonstrating the distribution of the significantly changed lipids in the group-to-group comparison. Abbreviations: CL, cardiolipin; DAG, diacylglycerol; EtherLPC, ether-linked lysophosphatidylcholine; EtherLPE, ether-linked lysophosphatidylethanolamine; EtherPE, ether-linked phosphatidylethanolamine; FFA, free fatty acids; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin; TAG, triacylglycerol.</p></caption><graphic xlink:href="ijms-20-05952-g003"/></fig><fig id="ijms-20-05952-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Bubble plots showing the relevant information of the significantly perturbed lipids in (<bold>A</bold>) EV-A71-infected vs. mock-infected cells and (<bold>B</bold>) CV-A16-infected vs. mock-infected cells, respectively. The X-axis is the retention time of lipids in chromatography separation. The Y-axis is the log<sub>2</sub> fold change in abundance of each lipid in virus-infected cells relative to mock-infected cells. The size of each bubble represents the statistical significance of that change (<italic>p</italic> value by Student t-test: The larger the size, the smaller the <italic>p</italic> value). Abbreviations: AA, arachidonic acid; CL, cardiolipin; DAG, diacylglycerol; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; EtherLPC, ether-linked lysophosphatidylcholine; EtherLPE, ether-linked lysophosphatidylethanolamine; EtherPE, ether-linked phosphatidylethanolamine; FFA, free fatty acids; hpi, hours post-infection; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin; TAG, triacylglycerol.</p></caption><graphic xlink:href="ijms-20-05952-g004"/></fig><fig id="ijms-20-05952-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Box-whisker plots of the four fatty acid classes that were significantly upregulated in both EV-A71 and CV-A16-infected RD cells. The normalized peak heights were generated by LC-MS raw data after DNA normalization. Abbreviations: CV-A16, CV-A16-infected cells; EV-A71, EV-A71-infected cells; hpi, hours post-infection; Mock, mock-infect cells. * represented <italic>p</italic> &#x0003c; 0.05 and ** represented <italic>p</italic> &#x0003c; 0.01 (Student&#x02019;s <italic>t</italic>-test).</p></caption><graphic xlink:href="ijms-20-05952-g005"/></fig><fig id="ijms-20-05952-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Antiviral effects of the identified fatty acids against EV-A71 (<bold>A</bold>) and CV-A16 (<bold>B</bold>). RD cells were seeded into 96-well plates to reach 90% confluency for infection and then pre-incubated with lipid-supplemented medium at the following concentrations for 2 h: AA and DPA = 100 &#x000b5;M, DHA = 50 &#x000b5;M, and EPA = 60 &#x000b5;M. The lipids were dissolved in 2% ethanol and 2% ethanol alone was used as &#x0201c;Control&#x0201d;. The cells were then infected with either EV-A71 or CV-A16 (MOI = 10.0). At 1 hpi, the cells were washed three times with Dulbecco&#x02019;s modified eagle medium (DMEM) and then replenished with lipid-supplemented medium for 4 h of incubation. The cell lysates were then collected for qRT-PCR. Data represented means and standard deviations. Abbreviations: AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; hpi, hours post-infection.</p></caption><graphic xlink:href="ijms-20-05952-g006"/></fig><table-wrap id="ijms-20-05952-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-05952-t001_Table 1</object-id><label>Table 1</label><caption><p>Lipids that were significantly different among EV-A71-infected, CV-A16-infected, and mock-infected samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Significant Lipids</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Detection Mode</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Retention Time</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Accurate Mass in Detection Mode</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Adduct Ion Name</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Lipid Class</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Identification Information</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value in EV71 Infection vs Mock</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value in CA16 Infection vs Mock</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value in CA16 vs EV71 Infection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fold Change in EV71 Infection vs Mock</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fold Change in CA16 Infection vs Mock</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fold Change in CA16 vs EV71 Infection</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Arachidonic acid</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">303.2315</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">FFA</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">STD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54</td><td align="center" valign="middle" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Docosahexaenoic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.94</td><td align="center" valign="middle" rowspan="1" colspan="1">327.2319</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">FFA</td><td align="center" valign="middle" rowspan="1" colspan="1">STD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0196</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Docosapentaenoic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">2.19</td><td align="center" valign="middle" rowspan="1" colspan="1">329.2466</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">FFA</td><td align="center" valign="middle" rowspan="1" colspan="1">STD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0095</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Eicosapentaenoic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">301.2167</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">FFA</td><td align="center" valign="middle" rowspan="1" colspan="1">STD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0382</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0096</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" rowspan="1" colspan="1">1.58</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adrenic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">2.78</td><td align="center" valign="middle" rowspan="1" colspan="1">331.2624</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">FFA</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0067</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">1.55</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL (16:0/18:1/16:0/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">15.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1403.989</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49</td><td align="center" valign="middle" rowspan="1" colspan="1">1.71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL (70:5)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">15.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1425.9708</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47</td><td align="center" valign="middle" rowspan="1" colspan="1">1.71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL (16:1/18:0/18:1/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">15.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1430.004</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" rowspan="1" colspan="1">2.31</td><td align="center" valign="middle" rowspan="1" colspan="1">2.54</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL (72:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">15.36</td><td align="center" valign="middle" rowspan="1" colspan="1">1456.0192</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">2.87</td><td align="center" valign="middle" rowspan="1" colspan="1">4.30</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SM (d14:2/28:2)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">13.08</td><td align="center" valign="middle" rowspan="1" colspan="1">809.6527</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">SM</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0013</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SM (d18:1/24:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">13.06</td><td align="center" valign="middle" rowspan="1" colspan="1">813.6888</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">SM</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SM (d18:0/24:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">13.29</td><td align="center" valign="middle" rowspan="1" colspan="1">815.6979</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">SM</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SM (d18:1/24:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">13.67</td><td align="center" valign="middle" rowspan="1" colspan="1">815.7034</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">SM</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC (O-16:0/0:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">1.57</td><td align="center" valign="middle" rowspan="1" colspan="1">482.363</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherLPC</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">1.97</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC (16:1/0:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">494.3254</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">LPC</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0027</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0011</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC (18:1/0:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42</td><td align="center" valign="middle" rowspan="1" colspan="1">522.3575</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">LPC</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC (16:0/20:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">6.51</td><td align="center" valign="middle" rowspan="1" colspan="1">782.5679</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">PC</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0204</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC (20:4/20:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">5.15</td><td align="center" valign="middle" rowspan="1" colspan="1">830.5708</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">PC</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC (20:3/20:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">5.89</td><td align="center" valign="middle" rowspan="1" colspan="1">832.5861</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">PC</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-16:0/0:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">436.2826</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherLPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10</td><td align="center" valign="middle" rowspan="1" colspan="1">1.57</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (18:0/0:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96</td><td align="center" valign="middle" rowspan="1" colspan="1">480.3081</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">LPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-16:0/16:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">10.03</td><td align="center" valign="middle" rowspan="1" colspan="1">674.5099</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">3.92</td><td align="center" valign="middle" rowspan="1" colspan="1">4.02</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-16:0/17:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">688.5256</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">3.99</td><td align="center" valign="middle" rowspan="1" colspan="1">4.33</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-18:0/16:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">12.93</td><td align="center" valign="middle" rowspan="1" colspan="1">702.543</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04</td><td align="center" valign="middle" rowspan="1" colspan="1">2.22</td><td align="center" valign="middle" rowspan="1" colspan="1">2.13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-16:0/16:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">7.87</td><td align="center" valign="middle" rowspan="1" colspan="1">674.5112</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-16:0/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">10.09</td><td align="center" valign="middle" rowspan="1" colspan="1">700.5308</td><td align="center" valign="middle" rowspan="1" colspan="1">[M-H]&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14</td><td align="center" valign="middle" rowspan="1" colspan="1">6.49</td><td align="center" valign="middle" rowspan="1" colspan="1">5.72</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (O-16:0/18:2)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">10.34</td><td align="center" valign="middle" rowspan="1" colspan="1">702.5461</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (O-18:0/16:1(9Z))</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">12.94</td><td align="center" valign="middle" rowspan="1" colspan="1">704.5615</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01</td><td align="center" valign="middle" rowspan="1" colspan="1">2.37</td><td align="center" valign="middle" rowspan="1" colspan="1">2.35</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PE (P-18:0/18:2)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">10.51</td><td align="center" valign="middle" rowspan="1" colspan="1">728.5601</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+H]+</td><td align="center" valign="middle" rowspan="1" colspan="1">EtherPE</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DG (18:1/18:1/0:0)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">13.16</td><td align="center" valign="middle" rowspan="1" colspan="1">638.5742</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">DAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DG (38:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">13.14</td><td align="center" valign="middle" rowspan="1" colspan="1">662.575</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">DAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0030</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (44:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.07</td><td align="center" valign="middle" rowspan="1" colspan="1">766.692</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0033</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (46:2)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.09</td><td align="center" valign="middle" rowspan="1" colspan="1">792.7092</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0069</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (14:0/16:0/16:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.41</td><td align="center" valign="middle" rowspan="1" colspan="1">794.7274</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0112</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (47:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.57</td><td align="center" valign="middle" rowspan="1" colspan="1">808.7391</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0023</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">1.32</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (14:1/16:1/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.11</td><td align="center" valign="middle" rowspan="1" colspan="1">818.7252</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0066</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (14:0/16:1/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.43</td><td align="center" valign="middle" rowspan="1" colspan="1">820.7425</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0064</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (49:2)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.58</td><td align="center" valign="middle" rowspan="1" colspan="1">834.7562</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0022</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0026</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (16:1/16:1/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.45</td><td align="center" valign="middle" rowspan="1" colspan="1">846.7579</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0010</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0043</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (16:1/17:1/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.59</td><td align="center" valign="middle" rowspan="1" colspan="1">860.7723</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0031</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (14:0/18:1/20:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.34</td><td align="center" valign="middle" rowspan="1" colspan="1">870.757</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0137</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51</td><td align="center" valign="middle" rowspan="1" colspan="1">1.55</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (16:1/18:1/18:2)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.5</td><td align="center" valign="middle" rowspan="1" colspan="1">872.7713</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0031</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (16:0/18:1/18:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.99</td><td align="center" valign="middle" rowspan="1" colspan="1">876.7005</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0062</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (16:1/17:1/20:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.87</td><td align="center" valign="middle" rowspan="1" colspan="1">888.8029</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0077</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (54:5)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.64</td><td align="center" valign="middle" rowspan="1" colspan="1">898.7866</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0100</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG (16:0/18:1/22:5)</td><td align="center" valign="middle" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" rowspan="1" colspan="1">15.65</td><td align="center" valign="middle" rowspan="1" colspan="1">924.8024</td><td align="center" valign="middle" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0256</td><td align="center" valign="middle" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1.44</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TG (16:0/18:1/22:4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">926.8177</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[M+NH4]+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MS/MS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0326</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06</td></tr></tbody></table><table-wrap-foot><fn><p>MSMS = lipids that were confirmed with fragment pattern of database; NS = not significant; STD = lipids that were confirmed with authentic standards; The &#x02019;O-&#x02019; prefix is used to indicate the presence of an alkyl ether substituent, e.g., PC (O-16:0/0:0), whereas the &#x02019;P-&#x02019; prefix is used for the 1Z-alkenyl ether (Plasmalogen) substituent, e.g., PE (P-16:0/16:0). Abbreviations: CL, cardiolipin; DAG, diacylglycerol; EtherLPC, ether-linked lysophosphatidylcholine; EtherLPE, ether-linked lysophosphatidylethanolamine; EtherPE, ether-linked phosphatidylethanolamine; FFA, free fatty acid; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin; TAG, triacylglycerol.</p></fn></table-wrap-foot></table-wrap></floats-group></article>